X

Trial Profile

A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paltusotine (Primary)
Indications Acromegaly
Focus Registrational; Therapeutic Use
Acronyms PATHFNDR-2
Sponsors Crinetics Pharmaceuticals

Most Recent Events

03 Jun 2024 Results published in a Crinetics Pharmaceuticals media release
03 Jun 2024 According to a Crinetics Pharmaceuticals media release, data from this trial, presented today at the Endocrine Society's Annual Meeting (ENDO2024).
09 May 2024 According to a Crinetics Pharmaceuticals media release, company plans to submit an NDA in the second half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com